Aurobindo Pharma wins Perampanel approval: Aurobindo stock reflects 16.3 percent Q1 growth

Published on 10/20/2026 at 01:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 revenue reached INR 91.5 billion and net profit INR 10.3 billion. Aurobindo stock enters US dermatology after Adquey's launch.

Perampanel approval and growth

Aurobindo Pharma received Perampanel approval on October 3, 2026.
Q1 fiscal 2027 revenue reached INR 91.5 billion and net profit reached INR 10.3 billion.
The company entered a US dermatology market valued at USD 1.3 billion through Adquey.
November 14, 2026 is listed as the next earnings date.

Aurobindo, INE406A01037, Illustration mit AI erstellt.

Aurobindo Pharma received USFDA final approval for Perampanel tablets in six strengths on October 3, 2026, according to The Economic Times. Aurobindo stock also carries a stronger earnings base after first-quarter fiscal 2027 revenue rose 16.3 percent year over year to INR 91.5 billion, as reported by Sahi Markets.

Three recent growth signals

The approval followed several company developments. On September 16, 2026, JM Financial retained a Buy rating and saw up to 28 percent upside, according to The Economic Times. On September 30, Aurobindo launched Adquey in the United States and established a dedicated dermatology business, the same page reported.

On October 1, 2026, Acrotech commercialized Adquey for atopic dermatitis in the United States. Sahi Markets placed the target dermatology market at USD 1.3 billion and described the launch as a move beyond generic and oncology products.

What does the approval change?

The commercial opportunity now combines a new specialty product with stronger recent earnings. First-quarter fiscal 2027 net profit rose 25.2 percent year over year to INR 10.3 billion, while the Perampanel approval expands the generic portfolio. The company develops and sells generic medicines, active pharmaceutical ingredients and injectables across India, the United States and Europe.

Chronology points to portfolio expansion

The recent sequence is clear: JM Financial cited up to 28 percent upside on September 16, 2026; Adquey entered the United States and Aurobindo established a dermatology unit on September 30, 2026; and Perampanel gained USFDA final approval on October 3, 2026. The sequence links specialty commercialization with additional regulatory approvals.

Next reporting date

Simply Wall St lists November 14, 2026 as Aurobindo Pharma's next earnings date. That report will show whether first-quarter growth carries into the September quarter.

Indian quote and valuation context

Aurobindo Pharma was last at INR 1,621.40 on the NSE on October 19, 2026 at 3:29 p.m. IST. Its market capitalization was INR 932.9 billion, while the 52-week range was INR 1,080.10 to INR 1,740.00 on the same market-data snapshot.